FDA Declines Approval for Lung Cancer Drug Ivonescimab
Federal regulators have turned down an application for the investigational cancer treatment ivonescimab, pointing to a lack of statistically significant overall survival benefits in late-stage trials.
🧠AI AnalysisPhoto: medpagetoday.com
Key points
- FDA issues complete response letter for ivonescimab
- Trial showed progression-free survival gains but lacked overall survival significance
- Drug continues testing in multiple ongoing global clinical trials
The U.S. Food and Drug Administration (FDA) has declined to approve ivonescimab, a closely watched bispecific antibody developed to target PD-1 and VEGF, according to an announcement by drugmaker Summit Therapeutics. The regulatory agency issued a complete response letter stating that the treatment could not be cleared for non-small cell lung cancer because a pivotal phase III trial did not establish a statistically significant overall survival advantage.
During the HARMONi trial, researchers evaluated the medication alongside platinum-containing chemotherapy for patients with advanced or metastatic non-small cell lung cancer who had previously undergone treatment with EGFR inhibitors. While the combination successfully extended progression-free survival to a median of 6.8 months compared with 4.4 months for the placebo group, the overall survival data showed a numerical difference of 16.8 months versus 14 months that fell short of statistical significance. Regulators concluded that the progression-free survival benefit alone was insufficient to establish a favorable benefit-risk profile for approval.
Despite this regulatory setback, the therapy maintains approvals for several lung cancer indications in China and continues to be evaluated in multiple ongoing global clinical investigations. Researchers are currently assessing the drug in various settings, including frontline treatments and other solid tumor types such as colorectal and renal cell carcinomas. Patients considering clinical trials or emerging therapies should consult their healthcare provider to discuss personal treatment decisions.
What to know
- Regulatory Action: The FDA rejected ivonescimab due to an insufficient overall survival benefit in phase III trials.
- Trial Metrics: Progression-free survival improved significantly, but overall survival failed to reach statistical significance.
- Ongoing Research: The drug remains under evaluation in several international clinical trials for various lung and solid tumor cancers.
Source medpagetoday.com — medpagetoday.com/hematologyoncology/lungcancer/123904 ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.